Vincerx Pharma (VINC)
(Delayed Data from NSDQ)
$0.65 USD
-0.03 (-4.43%)
Updated Jul 29, 2024 03:59 PM ET
After-Market: $0.64 -0.01 (-1.52%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Vincerx Pharma, Inc. [VINC]
Reports for Purchase
Showing records 1 - 6 ( 6 total )
Company: Vincerx Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Vincerx Pharma, Inc.
Industry: Medical - Biomedical and Genetics
4Q 2021 Results; Significant Progress in 2021 and 2022. Reiterate Buy and Increasing our PT from $25 to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Vincerx Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data on Selective CDK9 Inhibitor, VIP152, to be Presented at AACR; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Vincerx Pharma, Inc.
Industry: Medical - Biomedical and Genetics
VIP236 Targets Cancer Cells and Protects Healthy Tissue From Chemo; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Vincerx Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Do You C What We C(DK)? Initiating at Buy and Price Target of $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Vincerx Pharma, Inc.
Industry: Medical - Biomedical and Genetics
|